CPhI North America Conference
The CPhI North America Conference is expected to draw more than 7,500 attendees representing the entire pharma eco-system in North America, the largest pharmaceutical market in the world. Topics to be addressed include formulation trends for topical dosage forms, outsourcing trends, and regulatory changes on the horizon. Louis Scotti, Vice President, Business Development at IriSys, will be leading discussions with industry executives interested in the Company’s approach to the development of new drugs, from formulation research and development to manufacturing solutions for pharmaceutical ingredients. “Many conference attendees are seeking experienced partners to provide cost-effective services that take their products from early discovery to commercialization,” said Louis Scotti, IriSys’ Vice President, Business Development. “IriSys has a successful track record with drugs of various classes and physicochemical properties. Our areas of expertise include formulation development, analytical methods development, regulatory and drug development, cGMP clinical supply manufacturing, and commercial manufacturing of specialty pharmaceuticals.” Regulatory issues are an industry “hot topic” at the conference. IriSys supports its clients’ regulatory needs by offering strategic consulting services that include drug development guidance and regulatory strategies at all stages of the U.S. Food and Drug Administration (FDA) drug approval process, as well as special assistance for international clients. “We serve as our clients’ development partner from planning for initial FDA meetings to the commercialization of their products,” Scotti noted.